Share This Page

Alzheimer's And Dementia Weekly

Support & Insight for the Autumn of Life

Have an account?

Drugs

Leqembi Becomes Europe’s First Alzheimer’s Antibody

April 16, 2025 No Comments

The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.

Study authors David Gate (left) and Lynn van Olst (right) compare two slides containing human brain tissue. Brown amyloid beta plaques are visible in the left slide, which contains brain tissue with Alzheimer's Disease that had not been treated. The slide on the right, which contains brain tissue that had been treated, does not show amyloid plaques.

Can the New Alzheimer’s Drugs Work Even Better?

March 10, 2025 No Comments

The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.

Close-up of doctor writing prescription with medicines and stethoscope on desk.

Advantages of Namzaric for Dementia

February 20, 2025 5 Comments

ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.

Alzheimer’s, Bathroom Trips & Cholinesterase Inhibitors

February 19, 2025 No Comments

Dementia’s cholinesterase inhibitors can affect trips to the bathroom, according to researchers in Houston, Texas. Learn more if you take donepezil, rivastigmine or galantamine. (Brand names Adlarity, Aricept, Ebixa, Exelon, Namzaric, Razadyne)

An infusion of antibody therapy for Alzheimer's. (Courtesy of WashU Medicine news release using Getty Images)

Leqembi & Kisunla: Extending Independent Living

February 16, 2025 1 Comment

A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.

Leqembi: Europe Checks It’s Safety; U.S. Approves Monthly Doses

February 3, 2025 No Comments

The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.

woman in white shirt holding clear plastic iv bag

What’s Ahead for Alzheimer’s Drugs in 2025

January 12, 2025 No Comments

Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Alzheimer's Amyloid Plaques choking neurons

Is Leqembi Shrinking the Alzheimer’s or the Brain?

January 5, 2025 1 Comment

Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.

Science Director Discussing Lecanemab (Leqembi)

Why Did Europe Finally Choose Lecanemab for Alzheimer’s?

November 28, 2024 No Comments

Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?

Person with dementia and partner on door step

Catching Up to America: Europe Recommends Leqembi® for Alzheimer’s

November 17, 2024 No Comments

The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.

Dementia 101 in 101 Seconds

July 10, 2026

VIDEO:

Understand dementia better. Get helpful insights and key facts.

Less Sugar, More Memory

July 9, 2026

DIET VIDEO + ARTICLE: Healthy? Normal blood sugar? No diabetes? Even so, find out how the more sugar you eat, the less memory you get.

Sugar Ups Dementia – Every Bit Counts

July 9, 2026

ASTONISHING VIDEO & ARTICLE: Dementia-risk was tested for 17 sugar levels in 2000 people. Each higher level bumped up the risk, without exception. See why researchers found these results so compelling.

Most Popular Stories

85 with Dementia? Good Chance It’s HS-AGING, Not Alzheimer’s

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?

Grandmother in black and white striped shirt hugging girl in black and white striped shirt

A Grandchild for One Day Keeps Dementia Away

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

“I’ve Got You Under My Skin,” By Dad with Dementia & Son

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

Is Alzheimer’s Catchy?

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.